{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:14Z","timestamp":1788401594192,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"(NIH)","award":["AI068634"],"award-info":[{"award-number":["AI068634"]}]},{"name":"(NIH)","award":["AI068636"],"award-info":[{"award-number":["AI068636"]}]},{"name":"(NIH)","award":["AI106701"],"award-info":[{"award-number":["AI106701"]}]},{"name":"(NIH)","award":["AI150396"],"award-info":[{"award-number":["AI150396"]}]},{"name":"(NIH)","award":["AI060354"],"award-info":[{"award-number":["AI060354"]}]},{"name":"(NIH)","award":["AI164560"],"award-info":[{"award-number":["AI164560"]}]},{"name":"(NIH)","award":["AI157875"],"award-info":[{"award-number":["AI157875"]}]},{"DOI":"10.13039\/100017540","name":"Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases, NIH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021671","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021671","id-type":"DOI","asserted-by":"publisher"}]},{"name":", NIH","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A key research priority for developing a human immunodeficiency virus (HIV) cure strategy is to define the viral dynamics and biomarkers associated with sustained posttreatment control. The ability to predict the likelihood of sustained posttreatment control or noncontrol could minimize the time off antiretroviral therapy (ART) for those destined to be controllers and anticipate longer periods off ART for those destined to be controllers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Mathematical modeling and machine learning were used to characterize virologic predictors of long-term virologic control, using viral kinetics data from several studies in which participants interrupted ART. Predictors of post-ART outcomes were characterized using data accumulated from the time of treatment interruption, replicating real-time data collection in a clinical study, and classifying outcomes as either posttreatment control (plasma viremia, \u2264400\u2005copies\/mL at 2 of 3 time points for \u226524 weeks) or noncontrol.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Potential predictors of virologic control were the time to rebound, the rate of initial rebound, and the peak plasma viremia. We found that people destined to be noncontrollers could be identified within 3 weeks of rebound (prediction scores: accuracy, 80%; sensitivity, 82%; specificity, 71%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Given the widespread use of analytic treatment interruption in cure-related trials, these predictors may be useful to increase the safety of analytic treatment interruption through early identification of people who are unlikely to become posttreatment controllers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae551","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:26:46Z","timestamp":1730953606000},"page":"e419-e428","source":"Crossref","is-referenced-by-count":6,"title":["Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption"],"prefix":"10.1093","volume":"231","author":[{"given":"Gesham","family":"Magombedze","sequence":"first","affiliation":[{"name":"Biology Department, Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-1773","authenticated-orcid":false,"given":"Elena","family":"Vendrame","sequence":"additional","affiliation":[{"name":"Biology Department, Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"SenGupta","sequence":"additional","affiliation":[{"name":"Biology Department, Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romas","family":"Geleziunas","sequence":"additional","affiliation":[{"name":"Biology Department, Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-9737","authenticated-orcid":false,"given":"Susan","family":"Little","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California , San Diego, La Jolla, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davey","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California , San Diego, La Jolla, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Walker","sequence":"additional","affiliation":[{"name":"The Ragon Institute of Mass General, MIT, and Harvard , Cambridge, Massachusetts ,","place":["USA"]},{"name":"Howard Hughes Medical Institute , Chevy Chase, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-7589","authenticated-orcid":false,"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[{"name":"Division of Hematology and Chronic Viral Illness Service, McGill University Health Centre: Glen Site Research Institute , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick M","family":"Hecht","sequence":"additional","affiliation":[{"name":"Osher Center for Integrative Health, University of California , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Wook","family":"Chun","sequence":"additional","affiliation":[{"name":"Laboratory of Immunoregulation, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2816-7905","authenticated-orcid":false,"given":"Michael","family":"Sneller","sequence":"additional","affiliation":[{"name":"Laboratory of Immunoregulation, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-9662","authenticated-orcid":false,"given":"Jonathan Z","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Deeks","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases, and Global Medicine, University of California , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-6230","authenticated-orcid":false,"given":"Michael J","family":"Peluso","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases, and Global Medicine, University of California , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"2025022016333856000_jiae551-B1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3389\/fimmu.2019.01749","article-title":"Learning from the exceptions: HIV remission in post-treatment controllers","volume":"10","author":"Etemad","year":"2019","journal-title":"Front Immunol"},{"key":"2025022016333856000_jiae551-B2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","article-title":"Prevention, treatment and cure of HIV infection","volume":"21","author":"Landovitz","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2025022016333856000_jiae551-B3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciab541","article-title":"Time to viral rebound after interruption of modern antiretroviral therapies","volume":"74","author":"Li","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025022016333856000_jiae551-B4","doi-asserted-by":"crossref","first-page":"ofw100","DOI":"10.1093\/ofid\/ofw100","article-title":"Antibody responses after analytic treatment interruption in human immunodeficiency virus-1-infected individuals on early initiated antiretroviral therapy","volume":"3","author":"Stephenson","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2025022016333856000_jiae551-B5","doi-asserted-by":"crossref","first-page":"648434","DOI":"10.3389\/fmicb.2021.648434","article-title":"Predicting post-treatment HIV remission: does size of the viral reservoir matter?","volume":"12","author":"Pasternak","year":"2021","journal-title":"Front Microbiol"},{"key":"2025022016333856000_jiae551-B6","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J Infect Dis"},{"key":"2025022016333856000_jiae551-B7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/infdis\/jiac032","article-title":"Balancing statistical power and risk in HIV cure clinical trial design","volume":"226","author":"Lau","year":"2022","journal-title":"J Infect Dis"},{"key":"2025022016333856000_jiae551-B8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11904-021-00569-8","article-title":"Analytical treatment interruption in HIV trials: statistical and study design considerations","volume":"18","author":"Zheng","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"suppl 1","key":"2025022016333856000_jiae551-B9","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/infdis\/jiz036","article-title":"Preexposure prophylaxis for mitigating risk of HIV transmission during HIV cure-related clinical trials with a treatment interruption","volume":"220","author":"Leli\u00e8vre","year":"2019","journal-title":"J Infect Dis"},{"key":"2025022016333856000_jiae551-B10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2055-6640(20)30009-1","article-title":"A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption","volume":"6","author":"Peluso","year":"2020","journal-title":"J Virus Erad"},{"key":"2025022016333856000_jiae551-B11","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting","volume":"6","author":"Julg","year":"2019","journal-title":"Lancet HIV"},{"key":"2025022016333856000_jiae551-B12","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/cid\/ciaa1260","article-title":"Operationalizing human immunodeficiency virus cure-related trials with analytic treatment interruptions during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic: a collaborative approach","volume":"72","author":"Peluso","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025022016333856000_jiae551-B13","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.jve.2020.100025","article-title":"HIV cure research in the time of COVID-19\u2014antiretroviral therapy treatment interruption trials: a discussion paper","volume":"7","author":"Fidler","year":"2021","journal-title":"J Virus Erad"},{"key":"2025022016333856000_jiae551-B14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/QAD.0000000000000658","article-title":"The need for treatment interruption studies and biomarker identification in the search for an HIV cure","volume":"29","author":"Li","year":"2015","journal-title":"AIDS"},{"key":"2025022016333856000_jiae551-B15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/vaccines8030442","article-title":"Antiretroviral therapy interruption (ATI) in HIV-1 infected patients participating in therapeutic vaccine trials: surrogate markers of virological response","volume":"8","author":"Leal","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2025022016333856000_jiae551-B16","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/QAD.0b013e32832eb285","article-title":"Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment","volume":"23","author":"Volberding","year":"2009","journal-title":"AIDS"},{"key":"2025022016333856000_jiae551-B17","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1086\/509508","article-title":"A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)","volume":"194","author":"Kilby","year":"2006","journal-title":"J Infect Dis"},{"key":"2025022016333856000_jiae551-B18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1086\/506364","article-title":"Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS clinical trials group 5068","volume":"194","author":"Jacobson","year":"2006","journal-title":"J Infect Dis"},{"key":"2025022016333856000_jiae551-B19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/01.qai.0000225319.59652.1e","article-title":"A pilot study evaluating time to CD4 T-cell count &lt;350 cells\/mm3 after treatment interruption following antiretroviral therapy +\/- interleukin 2: results of ACTG A5102","volume":"42","author":"Henry","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025022016333856000_jiae551-B20","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1016\/j.vaccine.2009.05.016","article-title":"A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy","volume":"27","author":"Gandhi","year":"2009","journal-title":"Vaccine"},{"key":"2025022016333856000_jiae551-B21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJM200102153440702","article-title":"Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia","volume":"344","author":"Deeks","year":"2001","journal-title":"N Engl J Med"},{"key":"2025022016333856000_jiae551-B22","doi-asserted-by":"crossref","first-page":"e10555","DOI":"10.1371\/journal.pone.0010555","article-title":"Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute\/early HIV-1 infection","volume":"5","author":"Rosenberg","year":"2010","journal-title":"PLoS One"},{"key":"2025022016333856000_jiae551-B23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/655468","article-title":"AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein","volume":"202","author":"Schooley","year":"2010","journal-title":"J Infect Dis"},{"key":"2025022016333856000_jiae551-B24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00126334-200008150-00004","article-title":"Comparison of clinical features of acute HIV-1 infection in patients infected sexually or through injection drug use: the investigators of the Quebec primary HIV infection study","volume":"24","author":"Routy","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025022016333856000_jiae551-B25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1258\/ijsa.2011.011178","article-title":"Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle primary infection cohort vary by control group","volume":"23","author":"Stekler","year":"2012","journal-title":"Int J STD AIDS"},{"key":"2025022016333856000_jiae551-B26","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/QAD.0000000000000816","article-title":"No evidence of posttreatment control after early initiation of antiretroviral therapy","volume":"29","author":"Gianella","year":"2015","journal-title":"AIDS"},{"key":"2025022016333856000_jiae551-B27","doi-asserted-by":"crossref","first-page":"eaan8848","DOI":"10.1126\/scitranslmed.aan8848","article-title":"A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection","volume":"9","author":"Sneller","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025022016333856000_jiae551-B28","doi-asserted-by":"crossref","first-page":"e15510","DOI":"10.1371\/journal.pone.0015510","article-title":"Transmitted drug resistance in persons with acute\/early HIV-1 in San Francisco, 2002\u20132009","volume":"5","author":"Jain","year":"2010","journal-title":"PLoS One"},{"key":"2025022016333856000_jiae551-B29","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1126\/science.1195271","article-title":"The major genetic determinants of HIV-1 control affect HLA class I peptide presentation","volume":"330","author":"Pereyra","year":"2010","journal-title":"Science"},{"key":"2025022016333856000_jiae551-B30","doi-asserted-by":"crossref","first-page":"eabg3071","DOI":"10.1126\/scitranslmed.abg3071","article-title":"The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy","volume":"13","author":"SenGupta","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025022016333856000_jiae551-B31","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: global scientific strategy 2021","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat Med"},{"key":"2025022016333856000_jiae551-B32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13063-022-06151-w","article-title":"The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial","volume":"23","author":"Lee","year":"2022","journal-title":"Trials"},{"key":"2025022016333856000_jiae551-B33","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1038\/s41591-022-02060-2","article-title":"Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial","volume":"28","author":"Bailon","year":"2022","journal-title":"Nat Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae551\/60541683\/jiae551.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/2\/e419\/60541683\/jiae551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/2\/e419\/60541683\/jiae551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:34:03Z","timestamp":1740069243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/2\/e419\/7887579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,8]]},"published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae551","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,11,8]]}}}